Alijaj N, Moutel S, Gouveia Z, Gray M, Roveri M, Dzhumashev D, et al. Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. Cancers (Basel). 2020;12: pubmed publisher

Tohyama O, Matsui J, Kodama K, Hata Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747 pubmed publisher

Sokolowska Wedzina A, Borek A, Chudzian J, Jakimowicz P, Zakrzewska M, Otlewski J. Efficient production and purification of extracellular domain of human FGFR-Fc fusion proteins from Chinese hamster ovary cells. Protein Expr Purif. 2014;99:50-7 pubmed publisher

Zarczynska I, Gorska Arcisz M, Cortez A, Kujawa K, Wilk A, Skladanowski A, et al. p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer. Cells. 2021;10: pubmed publisher

Kitowska K, Gorska Arcisz M, Antoun D, Zarczynska I, Czaplinska D, Szczepaniak A, et al. MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells. Front Oncol. 2021;11:633410 pubmed publisher

Altunel E, Roghani R, Chen K, Kim S, McCall S, Ware K, et al. Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer. BMC Cancer. 2020;20:592 pubmed publisher

Fu T, Choi S, Kim D, Seok S, Suino Powell K, Xu H, et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor ?-Klotho. Proc Natl Acad Sci U S A. 2012;109:16137-42 pubmed publisher